Clinical Trials
69 trialsSTARTRK-2
Hoffmann-La Roche
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
iCaRe2
University of Nebraska
SJFAMILY
St. Jude Children's Research Hospital
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
TraveraRTGx
Travera Inc
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Nuvation Bio Inc.
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
TAILOR-EUS
IRCCS San Raffaele
18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
Nanjing First Hospital, Nanjing Medical University
RespEcran
Centre Georges Francois Leclerc
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly and Company
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Purple Biotech Ltd.
ROOT
Taproot Health
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
VISIONARY
Peking University
Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients
Yonsei University
RAPNEN
Catholic University of the Sacred Heart
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
HETERERO
Charite University, Berlin, Germany
ReSiPaTNE
University Hospital, Strasbourg, France
GEM
Georgetown University
ALpha-T
Hoffmann-La Roche
NutriGIT
University Medicine Greifswald
SEPTRALU
Sociedad Española de Medicina Nuclear e Imagen Molecular
Chromogranin A as Blood Marker in Cancer Patients
Brahms AG
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
Provectus Pharmaceuticals
LTW
Laser Tissue Welding, Inc.
Camune
University Hospital, Strasbourg, France
RESiN
Vanderbilt-Ingram Cancer Center
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
Cedars-Sinai Medical Center
PIONEER
SpeciCare
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
H. Lee Moffitt Cancer Center and Research Institute
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Grupo Espanol de Tumores Neuroendocrinos
PVNET
Royal Free Hospital NHS Foundation Trust
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
ACRIN7151
American College of Radiology Imaging Network
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Masonic Cancer Center, University of Minnesota